38.30 -0.70 (-1.79%)
After hours: 4:57PM EDT
|Bid||38.00 x 200|
|Ask||39.60 x 100|
|Day's Range||38.00 - 39.20|
|52 Week Range||7.50 - 41.80|
|PE Ratio (TTM)||-11.41|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||51.67|
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Zogenix, Inc. Here are 5 ETFs with the largest exposure to ZGNX-US. Comparing the performance and risk of Zogenix, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Findings Presented by Zogenix at the NORD Rare Diseases and Orphan Products Breakthrough Summit in Washington, D.C.. EMERYVILLE, Calif., Oct. 16, 2017-- Zogenix, Inc., a pharmaceutical company developing ...
EMERYVILLE, Calif., Oct. 05, 2017-- Zogenix, Inc., a pharmaceutical company developing therapies for the treatment of orphan and central nervous system disorders, announced today the closing of its previously ...
Categories: Yahoo FinanceGet free summary analysis Zogenix, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 7.13 million, Net Earnings of USD -22.45 million. Gross margins narrowed from 1.29% to -15.68% compared to the same period last year, operating (EBITDA) margins now -299.17% from -812.26%. Change in operating cash ... Read more (Read more...)
NEW YORK, NY / ACCESSWIRE / October 4, 2017 / All three of the U.S. major indexes reached new records for the second consecutive session as recent economic data continues to support a healthy U.S. economy. ...
Marijuana can reduce seizures in epilepsy patients, but Zogenix's ZX008 might control seizures even better.
EMERYVILLE, Calif., Oct. 02, 2017-- Zogenix, Inc., a pharmaceutical company developing therapies for the treatment of orphan and central nervous system disorders, announced today that it has priced an ...
Zogenix rocketed to its highest point in nearly seven years Monday after it announced a public offering of 4.3 million shares.
After reporting positive phase 3 results for its drug for Dravet syndrome last week, management announced a dilutive stock offering today to raise more capital.
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Zogenix, Inc. a score of 16. Our analysis is based on comparing Zogenix, Inc. with the following peers – DURECT Corporation, Mallinckrodt Plc, Merck & Co., Inc., Antares Pharma, Inc., Nektar Therapeutics, Johnson & Johnson, Cardinal Health, Inc., Eli Lilly and Company, Alkermes Plc and Pfizer Inc. ... Read more (Read more...)
NEW YORK, NY / ACCESSWIRE / October 2, 2017 / In the biotech world, it's often a race between pharma companies to get to the finish line with their drug candidates faster than others. Shares of GW Pharmaceuticals ...
LONDON, UK / ACCESSWIRE / October 2, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Zogenix, Inc. (NASDAQ: ZGNX ), following which we have published ...
EMERYVILLE, Calif., Oct. 02, 2017-- Zogenix, Inc., a pharmaceutical company developing therapies for the treatment of orphan and central nervous system disorders, announced today that it intends to offer ...
An experimental drug for a form of epilepsy saw strong early results, sending shares of an East Bay drug developer soaring Friday. Zogenix Inc. (ZGNX) said top-line results from a late-stage study of its drug, called ZX-008, showed that Dravet syndrome patients who were given the drug had fewer convulsive seizures than patients who received a placebo. A low dose of ZX-008, a liquid also known as fenfluramine hydrochloride, also showed improvements in the study's secondary targets, including an improvement in intervals between seizures.
Zogenix's low-dose fenfluramine may lower the rate of seizures in Dravet syndrome patients by more than GW Pharma's Epidiolex.
Zogenix rocketed Friday after reporting Phase 3 data of a seizure drug that widely topped earlier results from rival GW Pharma.
On Friday, shares of pharmaceutical company Zogenix Inc. (ZGNX) are skyrocketing after it announced positive results from its first Phase 3 study of ZX008, a drug used to treat the rare epilepsy form Dravet Syndrome.
Biotech news aplenty has breathed renewed life into the sector, driving those stocks and several ETFs to new highs.
Zogenix Inc's experimental treatment for a rare form of epilepsy met the main goal in a late-stage study, the company said on Friday, more than doubling the value of its shares and hurting those of peer GW Pharmaceuticals. In the trial, Zogenix's drug was superior to a placebo in reducing the number of seizures in children with Dravet syndrome, a genetic dysfunction in the brain.